Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
362 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (89)
  • (-) Currently Recruiting (15)
  • Closed (74)

Medical Condition

  • Show all (362)
  • Addiction (2)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (2)
  • Blood Disorders (1)
  • Bone & Muscle (2)
  • Cancer (109)
    • Bladder Cancer (1)
    • (-) Brain Cancer (9)
    • Breast Cancer (7)
    • Gastrointestinal (3)
    • Gynecologic Cancer (9)
    • Kidney Cancer (1)
    • Leukemia (8)
    • Liver Cancer (2)
    • (-) Lung Cancer (6)
    • Lymphoma (12)
    • Multiple Myeloma (8)
    • Pancreatic Cancer (7)
    • Prostate Cancer (6)
    • Skin Cancer (2)
  • COVID-19 (Coronavirus) (10)
  • Diabetes (9)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (44)
  • Heart Disease (24)
  • Infectious Disease (11)
  • Liver Disease (14)
  • Lung Disease (3)
  • Neurological Disorders (45)
  • Nutrition (1)
  • Obesity (8)
  • Obstetrics & Gynecology (12)
  • Pediatrics (26)
  • Psychiatric Disorders (8)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
Displaying 1 - 15 of 15

TIAN-SHAN1: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and Efficacy of DZD6008 in Patients with EGFR Mutant Advanced NSCLC

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This study is a Phase 1 clinical trial, which means it is the first stage of testing a new drug in humans to evaluate its safety, determine how the body processes it, and identify any potential side effects. The drug being studied, DZD6008, is investigational, meaning it has not been approved by the U.S. Food and Drug Administration (FDA). This study is…
Read More

COPERNICUS: A study to treat non-small cell lung cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab…
Read More

Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug, BDTX1535, which is not yet approved by the United States Food and Drug Administration (FDA), intreating patients with advanced solid tumors with changes in a protein named epidermal growth factor receptor (EGFR), which may or may not help your condition during…
Read More

Study of AZD9574 in Patients with Brain Cancer

Condition: Cancer / Brain Cancer
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug…
Read More

Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Currently Recruiting
The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called "study drugs" and are not approved by the…
Read More

Study of Focused Ultrasound (FUS) with DEFINITY Microbubbles in Children and Young Adults with Progressive Diffuse Midline Glioma (DMG)

Condition: Cancer / Brain Cancer
Investigator: James Hinkley Garvin Jr, MD
Status: Currently Recruiting
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Read More

Study of Lutathera in Patients with Glioblastoma (GB)

Condition: Cancer / Brain Cancer
Investigator: Mikhail Doubrovin, MD
Status: Currently Recruiting
The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted…
Read More

Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine). Lomustine (Gleostine) is already approved by the FDA for use in brain tumors but it is usually used alone and is not the first-line choice for…
Read More

Study of JNJ-86974680 Alone or in Combination with Cetrelimab and Radiotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Currently Recruiting
The purpose of this study is to find out if JNJ-86974680 taken by itself or together with Cetrelimab and radiotherapy can cause side effects which are unexpected or unwanted reactions. This is the first time that JNJ-86974680 is being used in people. Radiotherapy is also part of the study treatment and not part of your standard of care. JNJ-86974680 and…
Read More

Study of Eflornithine & Temozolomide in Patients with Glioblastoma Multiforme (GBM)

Condition: Cancer / Brain Cancer
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) or astrocytoma following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during…
Read More

Study of Durvalumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose this study to learn more about if a medication called durvalumab will work and be safe for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) with certain genetic changes when given in combination with tremelimumab and standard chemotherapy. Additionally, this study is being done to better…
Read More

Study of Sonocloud 9 in Patients with Glioblastoma (GBM)

Condition: Cancer / Brain Cancer
Investigator: Brian Gill, MD
Status: Currently Recruiting
The purpose of this study is to see if the implantable device, Sonocloud 9, is effective getting chemotherapy to better reach your tumor compared to receiving standard-of-care chemotherapy Temozolomide and Lomustine and to see how safe and tolerable the device is. Sonocloud 9 works by making the blood-brain barrier (BBB) more permeable (allowing liquids or…
Read More

Study of Osimertinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This study will compare the effectiveness of osimertinib alone to the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene for the epidermal growth factor receptor (EGFR). Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. This…
Read More

Study of PF-07799544 in Patients with Solid Brain Tumors

Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Currently Recruiting
The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with…
Read More

Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science